Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill help older adults regain strength?

NCT ID NCT07072195

Disease control Sponsor: Animuscure Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This clinical trial is testing whether an experimental oral drug called AMC6156 can improve physical function and safety in older adults with sarcopenia, a condition marked by loss of muscle mass and strength. Participants will take either AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be monitored through tests and checkups. The study aims to see if the drug can help improve mobility and quality of life in this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AMC6156
What this could lead to
If successful, this could lead to a new oral treatment to help older adults with sarcopenia regain strength and mobility, improving independence and quality of life.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not be conclusive. The drug may not prove more effective than placebo, and there could be side effects not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntary participation with written informed consent * Male ≥ 65 years or postmenopausal female * Diagnosed with sarcopenia: * ASM \< 7.0 kg/m² (men) or \< 5.4 kg/m² (women) * Plus low handgrip strength or SPPB ≤ 9 * MNA screening score ≥ 8 * Body weight ≥ 35 kg, BMI between 15-30 kg/m² * Willing and able to follow exercise and nutrition guidance Exclusion Criteria: * Allergy to investigational drug * History of GI bleeding, ulcers, or severe liver/kidney/heart disease * QTc ≥ 450 ms with symptoms * Severe COPD, uncontrolled diabetes or thyroid disease * Diseases causing cachexia or muscle wasting (e.g., ALS, Parkinson's) * Vitamin D deficiency (\<10 ng/mL), hemoglobin \<10 g/dL * Severe psychiatric disorders or MMSE \< 21 * Inability to walk or recent fracture/surgery affecting mobility * Use of prohibited medications or recent participation in other clinical trials * Investigator deems the subject unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenia Sarcopenia in elderly

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ajou University Hospital

    RECRUITING

    Suwon, Gyeonggi-do, 16499, South Korea

  • CHA Bundang Medical Center

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13496, South Korea

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.